Revvity, Inc. announced that Sophie Vandebroek and Michael Klobuchar have been elected to its board of directors, effective February 1, 2024. Dr. Vandebroek is the founder and owner of Strategic Vision Ventures, an innovation consulting firm. Previously, she was Massachusetts Institute of Technology?s Inaugural School of Engineering Visiting Scholar.

Until 2019 she was Vice President of Emerging Technology Partnerships at IBM. Dr. Vandebroek also served as the Chief Operating Officer of IBM Research. Prior to joining IBM, she was Chief Technology Officer and President of the Xerox Innovation Group.

Dr. Vandebroek led Xerox?s global laboratories, including PARC, Inc., where she was Chair of the board for eight years. Earlier in her career, Dr. Vandebroek was Xerox?s Chief Engineer and prior to that, VP of Xerox?s Canadian Research Center. She is also a member of the Board of Directors of IDEXX Laboratories (IDXX), Inari Agriculture, and Wolters Kluwer N.V. Previously Dr. Vandebroek served on the Board of Directors of Analogic and Nypro Corporation.

She holds 14 US patents and is a Fellow of the Institute of Electrical & Electronics Engineers (IEEE) and a Fellow of the Belgian-American Educational Foundation. Dr. Vandebroek holds a bachelor?s and master?s degree in electro-mechanical engineering from KU Leuven, Leuven, Belgium, and a Ph.D in electrical engineering from Cornell University. Mr. Klobuchar is Executive Vice President and Chief Strategy Officer at Merck & Co.

Inc. He is a member of Merck?s Executive Committee, and has served in his current role since 2021, overseeing the leadership, conception, planning and execution of strategies to achieve Merck?s vision, mission and business objectives. He is also responsible for setting and executing the company?s global business development and M&A strategies as well as leading the digital, data and IT infrastructure and cybersecurity strategies. Mr. Klobuchar prioritizes and pursues enterprise investment opportunities that modernize and expand the company?s innovation pipeline and technology portfolio across discovery, development, manufacturing and commercial.

He has guided the company through more than $25 billion in M&A activity over the last three years. Since joining Merck in 1998, Mr. Klobuchar has held positions of increasing responsibility in research, manufacturing, commercial planning, finance and strategy. Following the merger of Merck and Shering-Plough, he led key elements in the integration of the companies?

research operations. From 2019 to 2021, Mr. Klobuchar was Senior Vice President, CFO and Head of Portfolio and Alliance Management for Merck Research Laboratories, the company?s $13 billion research and development organization. Mr. Klobuchar holds an MBA from Villanova University, a master?s degree in chemical engineering from Rutgers University and a bachelor?s degree from Purdue University.